Jim Heather, Barata Anna, Wenham Robert, Jacobsen Paul
Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612 USA.
Hematology Service, Hospital de la Santa Creu i Sant Pau, Mas Casanova 90, 08004 Barcelona. Universitat Autonoma de Barcelona.
Int J Psychol Res (Medellin). 2013 Jun;6(1):8-14. doi: 10.21500/20112084.694.
The goal of this pilot study was to compare longitudinal changes in fatigue, depressive symptoms, sleep, and activity in women (n = 10) undergoing intraperitoneal (IP) versus intravenous (IV) chemotherapy for ovarian cancer. Fatigue and depressive symptoms were assessed via self -report and sleep and activity via wrist actigraphy in the week before and the week after the first infusion. Both groups demonstrated increases in fatigue and depressive symptoms, declines in sleep, reduced daytime activity, and decreased rhythmicity of sleep/activity patterns (p<.05). Effect sizes for within-group comparisons tended to be higher in the IP group (ds = -.15 to -8.03) than the IV group (ds = .12 to 1.40). Between-group comparisons revealed that IP patients demonstrated trends towards more severe symptoms post-chemotherapy in nearly all outcomes (p<.10). These results suggest that IP patients experience large increases in fatigue, depressive symptoms, and alterations in sleep and activity relative to IV patients.
这项初步研究的目的是比较接受腹腔内（IP）化疗与静脉内（IV）化疗的卵巢癌女性（n = 10）在疲劳、抑郁症状、睡眠和活动方面的纵向变化。在首次输注前一周和后一周，通过自我报告评估疲劳和抑郁症状，通过手腕活动记录仪评估睡眠和活动。两组均表现出疲劳和抑郁症状增加、睡眠减少、白天活动减少以及睡眠/活动模式的节律性降低（p<0.05）。组内比较的效应量在IP组（ds = -0.15至 -8.03）中往往高于IV组（ds = 0.12至1.40）。组间比较显示，IP患者在几乎所有结果中化疗后症状都有更严重的趋势（p<0.10）。这些结果表明，相对于IV患者，IP患者的疲劳、抑郁症状大幅增加，睡眠和活动也发生了改变。
